Peter Clausi
-
Hemostemix CEO on ACP’s Response to Ischemia in the Circulatory System
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
-
Lifton, Clausi, Cashin and Putnam on how the time for scandium is now
The Technology Metals Show hosts Jack Lifton and Peter Clausi talk to Peter Cashin, President and CEO of…
-
Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
-
Dr Dube and Greg Fenton on ZEN’s potential graphene-based antibiotic, antiviral and antifungal compound
In a recent InvestorIntel interview, Peter Clausi speaks with Dr. Francis Dube, Executive Chairman, and Greg Fenton, CEO…
-
Valeo Pharma on a significant upswing with recent Health Canada approvals
In a new InvestorIntel interview Peter Clausi speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH…
